Boston Tech
Mass General Got $25.8 Million to Send Gene Editors Into Blood Vessels
Mass General won up to $25.8 million from ARPA-H to build a reusable gene-editing platform for rare vascular diseases in Boston and beyond for patients.
Boston Tech
Apnimed Got Its Sleep Apnea Pill Into FDA Review, and Cambridge Sees a CPAP Exit Ramp
Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.
Startups
Voyage Health Wants AI to Sit Between Doom-Googling and Waiting Two Weeks
Voyage Health is a free AI health guidance app for iOS and Android with symptom conversations, wellness plans, memory, reminders, and follow-up tracking.
Boston Tech
Cogent Filed Its Third Bezuclastinib NDA, and Waltham Looks Weirdly Inevitable
Waltham-based Cogent filed an NDA for bezuclastinib in advanced systemic mastocytosis, turning a rare-disease bet into a serious 2026 launch race.
Boston Tech
Agios Posted New Sickle Cell Data, and Cambridge Gets a Rare Clean Win
Agios unveiled detailed Phase 3 sickle cell data on June 13, 2026, giving Cambridge biotech a real win in a field where progress is hard to earn.